VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2020 | To JAKi or not to JAKi – treating early MF

Ruben Mesa • 31 Aug 2020
Texas MPN Workshop 2020
Myeloproliferative Neoplasms Fedratinib Ruxolitinib

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the issues around early myelofibrosis, and how to treat patients, in particular considering disease burden when selecting a therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Ruben Mesa

2:24
MPN therapy: present strategies and future directions
Ruben Mesa • 19 Aug 2021
3:48
JAK inhibition for the early treatment of myelofibrosis
Ruben Mesa • 19 Aug 2021
2:21
Clinical updates on the use of momelotinib for MPNs
Ruben Mesa • 19 Aug 2021
1:15
Ongoing trials of ruxolitinib, momelotinib and imetelstat in myelofibrosis
Ruben Mesa • 2 Dec 2016

Related Videos

3:01
Update on Phase Ib trial of AVID200 in myelofibrosis
Ronald Hoffman • 16 Dec 2021
0:57
Myelofibrosis treatment in 5 years
Srdan Verstovsek • 16 Dec 2021
2:10
MANIFEST update: pelabresib clinical and pathological investigations
Srdan Verstovsek • 16 Dec 2021
7:26
Rusfertide: a promising option to control hematocrit levels in patients with polycythemia vera
Ronald Hoffman • 16 Dec 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals